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REGULAR ARTICLE
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Key Points
• The combination of
ruxolitinib and decita-
bine was generally well
tolerated in patients
with accelerated and
blast-phase MPN.
• The composite overall
response rate by
protocol-defined criteria
was 53% (42.9% by
intention-to-treat analy-
sis) in advanced phase
MPN.
Myeloproliferative neoplasms (MPN), including polycythemia vera, essential thrombocy-
themia, and primary myeloﬁbrosis, have a propensity to evolve into accelerated and blast-
phase disease (MPN-AP/BP), carrying a dismal prognosis. Conventional antileukemia therapy
has limited eﬃcacy in this setting. Thus,MPN-AP/BP is an urgent unmet clinical need.Modest
responses to hypomethylating agents and single-agent ruxolitinib have been reported. More
recently, combination of ruxolitinib and decitabine has demonstrated synergistic in vitro
activity in human andmurine systems. These observations led us to conduct a phase 1 study
to explore the safety of combined decitabine and dose-escalated ruxolitinib in patients with
MPN-AP/BP. A total of 21 patients were accrued to this multicenter study. Ruxolitinib was
administeredatdosesof 10, 15, 25, or50mg twicedaily incombinationwithdecitabine (20mg/m2
per day for 5 days) in 28-day cycles. The maximum tolerated dose was not reached. The most
common reasons for study discontinuation were toxicity/adverse events (37%) and disease
progression (21%). Fourteen patients died during study treatment period or follow-up. The
median overall survival for patients on study was 7.9 months (95% conﬁdence interval, 4.1-not
reached). Among evaluable patients, the overall response rate by protocol-deﬁned criteria
(complete remissionwith incomplete count recovery1partial remission)was 9/17 (53%) and by
intention-to-treat analysis was 9/21 (42.9%). The combination of decitabine and ruxolitinib was
generally well tolerated by patients with MPN-AP/BP and demonstrates potentially promising
clinical activity. A phase 2 trial evaluating the eﬃcacy of this combination regimen is ongoing
within the Myeloproliferative Disorder Research Consortium.
Introduction
Myeloproliferative neoplasm (MPN) carries an inherent risk of progression to an accelerated-phase
disease (AP; 10%-19% blasts in the peripheral blood or bone marrow), as well as to blast-phase disease
(BP;$20% blasts in the peripheral blood or bone marrow).1 The risk of disease progression is affected
by various clinical, biological, and genomic factors. The estimated risk of transformation of essential
thrombocythemia (ET) and polycythemia vera (PV), respectively, at 10 years from diagnosis is 1% and
4%. The risk of transformation of myelofibrosis at 10 years from diagnosis is ;20%.2
Submitted 9 April 2018; accepted 8 November 2018. DOI 10.1182/
bloodadvances.2018019661.
*R.K.R. and J.O.M. contributed equally to this work.
The full-text version of this article contains a data supplement.
© 2018 by The American Society of Hematology
3572 26 DECEMBER 2018 x VOLUME 2, NUMBER 24
.For personal use onlyon January 4, 2019. by guest  www.bloodadvances.orgFrom 
The prognosis of patients with MPN-AP/BP remains very poor,
with a median survival of 2.6 months.3,4 Importantly, chemotherapy
regimens used to treat acute myeloid leukemia (AML) appear to
have limited efficacy in this setting, with 1 series reporting a median
survival of 3.9 months for those treated with standard induction
chemotherapy; the study also reported treatment-related mortality
of 35%.3 To date, approaches using the hypomethylating agents
azacitidine (Vidaza) and decitabine (Dacogen) have been evaluated
in small series and have demonstrated activity in MPN-BP.
Azacitidine was evaluated in a group of MPN patients who had
progressed to AML or myelodysplastic syndrome and demon-
strated a 24% complete remission (CR) rate as well as an overall
response rate (ORR) of 52%.5 The use of decitabine in patients
with MPN-BP has demonstrated efficacy with a median survival
beyond 9 months at last reported follow-up.6 Data supporting
the use of the JAK1/2 inhibitor ruxolitinib (Jakafi) in MPN-BP
demonstrated a response to therapy in 3 of 18 AML patients (2 CR
and 1 CR with insufficient recovery of blood counts).7 In addition,
case reports have been published regarding the use of ruxolitinib in
combination with azacitidine or low-dose cytarabine in MPN-BP and
have demonstrated activity of these combinations.8
Recently, we described the first murine model of JAK2 V617F–driven
AML. Using this model, we tested several therapeutic concepts in
vitro, including the combination of ruxolitinib and decitabine. These
experiments demonstrated synergistic efficacy of this combination
regimen when compared with either agent alone.9 This observation,
together with prior clinical observations of the utility of hypomethylat-
ing agents and ruxolitinib as single-agent therapy in MPN-BP, led us
to conduct a phase 1 study to test the safety and efficacy of
combination ruxolitinib and decitabine (using escalating doses of
ruxolitinib and a fixed dose of decitabine) in patients with MPN-AP/
BP, as well as to identify a recommended phase 2 dose of ruxolitinib
to be used in combination with decitabine (NCT02076191). Ruxolitinib
is not approved alone or in combination with any other drug for
treatment of patients with MPN-AP/BP. Here we describe the
safety and clinical outcome data for this study.
Methods
This study was conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice guidelines. The
trial was designed and monitored by the Myeloproliferative Disease
Research Consortium. The protocol was approved by institutional
review boards at participating institutions. Written informed consent
was obtained from all patients before screening.
Patients aged 18 years or older with MPN-AP as defined by 10% to
19% blasts in the peripheral blood or bone marrow or a diagnosis of
MPN-BP as defined by $20% blasts in the blood or bone marrow,
following a previous diagnosis of ET, PV, or primary myelofibrosis
(MF), were recruited to the study. Eastern Cooperative Oncology
Group (ECOG) performance status scores of 0 through 3 were
eligible.
The primary aim of the study was to establish the MTD and
recommended phase 2 dose of ruxolitinib in combination with
decitabine by identifying the optimal dose of ruxolitinib that can be
administered concurrently with decitabine with an incidence,33%
nonhematologic grade 3 or higher toxicities as assessed using
the National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.0. For the purposes of assessing safety,
dose-limiting toxicities (DLT) were defined as those adverse events
(AE) occurring in the first 5 weeks (35 days) after initiation of therapy
that are not clearly related to disease or intercurrent illness. DLT were
defined as grade 3 or higher nonhematologic toxicity events not
clearly related to disease and grade 4 hematologic events with a
bone marrow cellularity of #5% and no evidence of leukemia.
Patients were enrolled in a standard 3 1 3 phase 1 design with an
MTD defined as a dose with ,33% DLT rate. Ruxolitinib was
administered in dose cohorts of 10, 15, 25, or 50 mg every 12 hours
in combination with decitabine at a dose of 20 mg/m2 intravenously
daily for 5 days and repeated every 28 days. During cycle 1,
ruxolitinib was administered as a single agent for 7 days; decitabine
was added on day 8 (Figure 1). Response assessment was carried
out every cycle using modified Cheson criteria10: CR required 0%
peripheral blood blasts, white blood cell $4 3 109/L, hemoglobin
$10 g/L, and platelets $100 3 109/L; CRi required 0% peripheral
blood blasts with incomplete count recovery; and partial remission
(PR) required$50% decrease in peripheral blood blasts regardless
of blood counts (supplemental Table 1). ORR included CR, complete
remission with incomplete count recovery (CRi), and PR. Overall
survival (OS) was defined as the time from first dose of ruxolitinib to
death by any cause. Patients were considered censored at the last
known date alive, if death was not documented. OS was estimated
using the Kaplan-Meier method.
The bone marrow aspirate is often unobtainable in patients with MF
and MPN-AP/BP because of fibrosis, thus preventing application of
classic World Health Organization therapeutic response assess-
ment. Further, discordance between bone marrow blast abundance
and peripheral blood blast count is often observed in MPN-AP/BP,
which may be due to extramedullary hematopoiesis.11 To date, no
validated uniform response criteria for MPN-AP/BP have been
established.12 We therefore adapted current World Health Orga-
nization AML response criteria to determine responses based on
peripheral blood counts; thus, response assessments are based
on clearance or decrease of peripheral blood blasts only. Best
responses were assessed at any point during treatment on or after
cycle 2 day 1 in 17 patients that were evaluable for response
assessment. Because of the use of peripheral blood blasts for
response assessment, 2 patients who had peripheral blasts of 0%
at baseline were unevaluable for therapeutic response. These
2 patients had 10% blasts in the bone marrow, thus meeting
eligibility criteria, and were evaluable for toxicity assessment.
Genomic and cytogenetic analysis
Assessment of genomic alterations was carried out in all patients at
baseline using the HemePACT assay, as previously described.13
Bone marrow metaphase cells were obtained using standard
technology and interphase fluorescence in situ hybridization scoring
and analysis was previously reported.14
Pharmacokinetic analysis
Plasma levels of ruxolitinib were assessed at predose and 0.5, 2.0,
and 4.0 hours after ruxolitinib administration during both the
ruxolitinib run-in phase (day 1) and the combination phase of
ruxolitinib and decitabine (day 8). Ruxolitinib plasma concentrations
were analyzed by validated liquid chromatography tandem mass
spectometry method as previously described. The quantification
limit of ruxolitinib was 0.3 ng/mL. The pharmacokinetic parameters
(time to reach maximum concentration, maximum serum concentration,
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and area under the curve from time 0 to last quantifiable concen-
tration [AUClast]) were calculated using noncompartmental analysis
by Phoenix WinNonlin (version 6.3, Certara USA, Princeton, NJ).
The drug–drug interactions were analyzed using a linear mixed
effects model. The model included treatment (combination of
ruxolitinib 1 decitabine or ruxolitinib alone) as fixed effects and
subject as a random effect. Estimates and confidence intervals
(CI) were first constructed in the logarithmic scale. By taking
antilogarithms, estimates and CI for the geometric means and ratios
of geometric means were derived.
Results
Patient characteristics
A total of 21 patients were accrued to study (Table 1; supplemental
Table 2). The median age was 63 years (range, 48-88). At the time
Screening
period
Days
-30 to 0
Days
1-7
Days
8 to 13
Days
14-35
Single agent
Ruxolitinib
Combination
Ruxolitinib and
Decitabine
Days
1 to 5
Days
6+Single agent Ruxolitinib
Induction phase
Single agent
Ruxolitinib
Combination
Ruxolitinib and
Decitabine
35 day
evaluable
phase I
portion
of study
Cycle 1
Cycles
2+
Extension
Figure 1. Myeloproliferative Disease Research Consor-
tium phase 1 study schema.
Table 1. Baseline patient demographics
10 mg bid (N 5 6) 15 mg bid (N 5 3) 25 mg bid (N 5 6) 50 mg bid (N 5 6) Total (N 5 21)
Age, median (range), y 62.0 (58.0-74.0) 63.0 (58.0-79.0) 66.5 (48.0-81.0) 72.0 (56.0-88.0) 63.0 (48.0-88.0)
Female/male, n (%) 3 (50.0)/3 (50.0) 1 (33.3)/2 (66.7) 2 (33.3)/4 (66.7) 2 (33.3)/4 (66.7) 8 (38.1)/13 (61.9)
ECOG 0-1, n (%) 3 (50.0) 3 (100.0) 5 (83.3) 4 (66.7) 15 (71.4)
ECOG 2-3, n (%) 3 (50.0) — 1 (16.7) 2 (33.3) 6 (28.6)
Disease duration before therapy, median (range), mo 137.8 (14.3-408.0) 114.6 (24.7-116.6) 168.1 (0.8-360.2) 27.0 (1.5-148.6) 85.3 (0.8-408.0)
Accelerated phase, n (%) 2 (33.3) — 3 (50.0) 3 (50.0) 8 (38.1)
Blast phase, n (%) 4 (66.7) 3 (100.0) 3 (50.0) 3 (50.0) 13 (61.9)
Spleen by palpation, median (range) 13 (0-19) 6 (6-6) 8.5 (0-15) 0 (0-13) 6 (0-19)
Prior ruxolitinib, n (%) 2 (33.3) — 1 (16.7) 3 (50.0) 6 (28.6)
Prior decitabine, n (%) 1 (16.7) 2 (66.7) 2 (33.3) — 5 (23.8)
Prior HSCT, n (%) — — 1 (16.7) — 1 (4.8)
bid, twice daily.
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of study enrollment, 8 (38.1%) carried a diagnosis of MPN-AP, and 13
(61.9%) carried a diagnosis of MPN-BP. Six (29%) and 5 (24%)
patients had prior exposure to ruxolitinib and decitabine, respectively.
One patient had failed prior allogeneic hematopoietic stem cell
transplantation (HSCT). At MPN presentation, 4 (19.1%) patients were
diagnosed with MPN-AP/BP, 8 (38%) with MF (primary or secondary),
8 (38%) with PV, and 1 (4.8%) with ET. The median duration of an
MPN diagnosis before enrollment on study was 85.3 months (range,
0.8-408). The median palpable spleen size below the left costal margin
at time of enrollment was 6 cm (range, 0-19). The majority of patients
had a performance status of ECOG 0-1 (15; 71.4%). JAK-STAT
activating mutations were observed in 18/21 (85.7%) of patients. The
most frequent non–JAK-STAT mutations occurred in splicing factors
(7/21, 33.3%), RUNX1 (5/21, 23.8%), TP53 (4/21, 19%), and TET2/
IDH1/2 (4/21, 19%). The median number of variants observed per
patient was 3 (range, 1-7). Normal karyotype was observed in 10/21
patients (47.6%); abnormal karyotype was detected in 9/21 patients
(43%). Cytogenetics was not available or inadequate in the remaining
2 patients. Complex karyotype with or without monosomal
karyotype was detected in 6 of 9 patients with an abnormal
karyotype (67% among abnormal, 28.5% of total), consistent with
the frequency of chromosomal abnormalities observed in advance
stages of MF. Four of these patients had monosomy or deletion of
chromosome 7, whereas 3 patients exhibited monosomy or del (5q).
Sole monosomy 7 was seen in 1 patient. One case of monosomy 17
resulting in loss of TP53 in 64% of interphase cells detected by
fluorescence in situ hybridization was observed in a patient with a
concomitant TP53 truncating mutation (supplemental Table 3).
Pharmacokinetic and drug–drug interaction analysis
Following oral administration of ruxolitinib alone or combination
administration of ruxolitinib and decitabine, time to reach maximum
concentration occurred from 0 to 4 hours postdose. Mean (6
standard deviation) AUClast values for ruxolitinib administered alone
or as combination with decitabine were 1310 (6 1970) and 998 (6
864) hours3 ng/mL, respectively. Geometric mean percentage ratios
(90% CI) of AUClast and maximum serum concentration (ruxolitinib 1
decitabine/ruxolitinib) were 97.47% (58.76%-161.67%) and 96.32%
Table 2. Adverse events by ruxolitinib dose level
10 mg bid (N 5 6) 15 mg bid (N 5 3) 25 mg bid (N 5 6) 50 mg bid (N 5 6) Total (N 5 21)
Hematologic, n (%)
Neutropenia 2 (33.4) 1 (33.3) 2 (33.3) 2 (33.3) 7 (33.3)
Grade 3 1 1 2 2 6
Grade 4 1 1
Febrile neutropenia 2 (33.3) 1 (33.3) 2 (33.3) 2 (33.3) 7 (33.3)
Grade 3 2 1 2 2 7
Lymphocytopenia 2 (33.3) 1 (16.7) 1 (16.7) 4 (19.0)
Grade 3 2 1 1 4
Thrombocytopenia 2 (33.3) 1 (33.3) 1 (16.7) 4 (19.0)
Grade 3 1 1 1 2
Grade 4 1 2
Anemia 1 (16.7) 1 (33.3) 1 (16.7) 3 (14.3)
Grade 3 1 1 1 3
Nonhematologic, n (%)
Pneumonia 3 (50) 1 (33.3) 1 (16.7) 1 (16.7) 6 (28.6)
Grade 3 3 1 1 1 6
Respiratory failure 2 (33.3) 2 (9.5)
Grade 3 1 1
Grade 4 1 1
Sepsis 1 (33.3) 1 (16.7) 1 (16.7) 3 (14.3)
Grade 4 1 1 1
Squamous cell carcinoma 2 (33.3) 2 (9.5)
Grade 3 2 2
Cellulitis 1 (16.7) 1 (16.7) 2 (9.5)
Grade 3 1 1
Gastrointestinal bleeding 1 (33.3) 1 (16.7) 2 (9.5)
Grade 3 1 1
Grade 4
Hypertension 1 (16.7) 1 (16.7) 2 (9.5)
Grade 3 1 1
Grade 4
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(59.31%-56.43%), respectively, indicating that the pharmacokinetics
of ruxolitinib and decitabine combination treatment is similar to
ruxolitinib alone and not affected by the combination treatment
(supplemental Figure 1).
Safety
All 21 enrolled patients were evaluable for AE assessment. No DLT
were observed in the 15- and 50-mg dose cohorts. One DLT event
(grade 3 laryngeal mucositis) occurred at the 10-mg dose level in the
first cohort of 3 patients. Thus, an additional 3 patients were enrolled
without the occurrence of a secondDLT. OneDLT event (grade 3 AST
increased) occurred at the 25-mg dose level in the first cohort of 3
patients. Thus, an additional 3 patients were enrolled at this dose level
without the occurrence of second DLT. The MTD was not reached.
The most frequent treatment emergent AE experienced by patients
(TEAEs) regardless of attribution (all grades) included; neutropenia (10
patients, 47.6%), thrombocytopenia (10 patients, 47.6%), and febrile
neutropenia (7 patients, 33.3%). Hematologic toxicity constituted the
majority of grades 3 and TEAE. Grade 3/4 hematologic AE occurring in
.5% of patients included neutropenia (7 patients, 33.3%), lympho-
penia (4 patients, 19%), thrombocytopenia (4 patients, 19%), and
anemia (3 patients, 14%). Grades 3 and 4 nonhematologic TEAE
regardless of attribution occurring in more than 5%of patients included
febrile neutropenia (7 patients, 33.3%), pneumonia (6 patients, 29%),
sepsis (3 patients, 14%), respiratory failure (2 patients, 9.5%),
hypertension (2 patients, 9.5%), cellulitis (2 patients, 9.5%),
gastrointestinal bleeding (2 patients, 9.5%), and squamous cell
carcinoma of the skin (2 patients, 9.5%) (Table 2). Grade 3 and
higher TEAE were comparable between patients with MPN-AP
vs MPN-BP (supplemental Table 4).
Response
Seventeen patients were evaluable for response. Four patients
were unevaluable for response assessment because of an absence
of baseline blasts (2 patients) and not completing cycle 1 day 35
(2 patients). CRi was observed in 4 (23.5%; 95% CI, 6.8-49.9)
patients (occurring at dose level 10 mg bid cycle 6, dose level 25
mg bid cycle 12, and dose level 50 mg bid cycles 2 and 6), PR was
observed in 5 (29.4%; 95% CI, 10.3-56.0) patients, and no
response was observed in 8 (47.1%; 95% CI, 23.0-72.2) of treated
patients. Response (CR1CRi1 PR) rate was 9/17 (53%; 95%C,
27.8-77.0) overall and was 4/6 (66.7%; 95% CI, 22.3-95.7) in
MPN-AP and 5/11 (45.5%; 95% CI, 16.8-76.6) in MPN-BP
patients. Using intention-to-treat analysis, the ORR was 9/21
(42.9%; 95% CI, 21.8-66.0); 4/8 (50.0%; 95% CI, 15.7%-84.3)
with MPN-AP and 5/13 (38.5%; 95% CI, 13.9-68.4) with MPN-BP.
The median number of cycles of therapy administered across all
dose cohorts was 3 (range, 1-34). Median peripheral blood blasts at
baseline was 10.5% (range, 0-76). Patients in the 10-mg ruxolitinib
dose cohort received the greatest number of cycles (median, 10.5;
range, 1-22) (Figure 2). The median blast percentage for these
patients at baseline was 10.5% and at time of response was 2.0%,
CR-I
PR
NR
Not evaluable
Response End
Su
bje
ct
s
Duration of treatment (cycles)
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36
Dose Level (mg) 10 15 25 50
Figure 2. Duration of treatment by ruxolitinib dose level.
Corresponding clinical responses are indicated by symbols.
End of response is defined as peripheral blood blast count
exceeding baseline value. NR, no response.
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splenomegaly at baseline. Dosing cohort designated by color.
*Unchanged spleen size.
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consistent with reversion to chronic phase disease (,10% blasts).
Reduction in peripheral blood blast percentage (Figure 3A) was
observed in all dosing cohorts. A median blast count reduction
of 57% (range, 8.4-100), in terms of maximum blast reduction
across all patients, was observed. The largest reduction in blast
percentage was observed in the 50-mg ruxolitinib dose cohort
(median, 91%; range, 2100 to 50) because 5 of 6 patients had
blast reductions at this dose followed by the 10-mg dosing cohort
(median, 60%; range, 2100 to 33). Importantly, among patients
attaining PR, all demonstrated a blast count #5% in the peripheral
blood at the time of response assessment. The median reduction in
spleen size across all dosing cohorts was 84.2% (range, 0-100),
with greatest reductions observed in the 15- and 25-mg ruxolitinib
doses (Figure 3B). Clinical responses (CRi or PR) were observed
in 1 of 2 evaluable patients (50%) with TP53 mutations, 2 of 4
evaluable patients (50%) with RUNX1 mutations, and 3 of 5
evaluable patients (60%) with splicing factor mutations. Clinical
responses were observed in 1 of 3 evaluable patients (33.3%) with
chromosome 7 abnormalities, 0 of 2 evaluable patients (0%) with
chromosome 17 abnormalities, and 5 of 9 patients (55.6%) with a
normal karyotype.
To date, 19 patients have ended treatment, 2 patients still currently
remain on therapy (1 patient in the 25-mg and 1 patient in the
50-mg cohorts). Reasons for ending treatment included: AE, 7
(36.8%); disease progression as assessed by the treating physician,
4 (21.1%); patient refused further treatment, 3 (15.8%); death,
2 (10.5%); other treatment, 2 (10.6%, including 1 patient who
underwent HSCT and 1 patient who received induction therapy
for AML);and investigator decision, 1 (5.3%). There have been 14
deaths to date. Causes of death were noted as sepsis/pneumonia,
5 (35.7%); relapse/progression, 4 (28.6%); unknown,: 2 (14.2%);
gastrointestinal hemorrhage, 1 (7.1%); circulatory failure, 1 (7.1%);
and cardiac arrest, 1 (7.1%). No deaths occurred within 30 days of
treatment. There were 2 deaths occurring,40 days after treatment
started. One death occurred at 36 days secondary to sepsis and a
second patient death occurred at 38 days because of circulatory
failure.
The median OS for patients on study was 7.9 months (95% CI, 4.1
months-not reached) (Figure 4). Survival did not differ by dosing
cohort. Median OS for MPN-AP patients was 16.0 months (95%CI,
4.7 -not reached) and was 7.2 months (95% CI, 2.2-not reached) in
MPN-BP patients. Median OS in responding patients was 10.9
months (95% CI, 7.9-not reached) vs 7.2 months in nonresponders
(95%CI, 3.3-14.4). No clear pattern of response based on molecular
genetic characteristics, spleen size, or baseline peripheral blood blast
count was observed (supplemental Tables 5 and 6).
Discussion
Therapy for patients with MPN-AP/BP remains a major unmet need.
In this multicenter phase 1 dose escalation trial, we demonstrated
that ruxolitinib administered up to a dose of 50 mg bid can be
combined with a fixed dose of decitabine without establishing an
MTD. Additionally, the ORR rate of 53% (42.9% by intention-to-
treat analysis) is encouraging considering the historical data of
standard AML induction chemotherapy, which has minimal benefit
outside of consolidation HSCT. Indeed, data from Mesa et al
demonstrate that patients with MPN-BP had a median survival of
3.9 months when treated with induction therapy vs 2.1 months for
those not receiving induction therapy.3 More recent retrospective
data from Kennedy et al15 demonstrate that MPN-BP patients
treated with curative intent (induction therapy followed by HSCT if
donor identified) had a median survival of 9.4 months vs 2.3 months
for those treated with noncurative intent (low-intensity therapy).
However, no significant difference in OS was detected between
patients treated with intensive chemotherapy who achieved a
response but did not go on to receive HSCT vs those patients
treated with nonintensive regimens (median survival, 9.4 vs 6.6
months, respectively). Importantly, induction therapy–related mor-
tality was;15%. These data suggest that in the absence of a viable
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Figure 4. Overall survival from the time of study enroll-
ment for the cohort as a whole.
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HSCT donor, a noninduction-based treatment regimen may offer a
less toxic and less clinically burdensome treatment approach. Our
data, demonstrating a median survival of 7.9 months compare
favorably with these data. Limitations of the study include the
heterogeneity of the population studied (comprising both MPN-AP
and MPN-BP), and the reliance on peripheral blood blast count for
response assessment owing to a lack of standard response criteria
as well as technical challenges involved in bone marrow assess-
ments in this patient population. Prospective data in a phase
2 setting is required to better assess the clinical benefit of this
combination therapy regimen. In addition, the clinical effect of
peripheral blast count clearance on long-term outcome remains to
be determined. Furthermore, data regarding the use of this regimen
before HSCT are needed to fully understand the applicability of this
approach to all patients with MPN-AP/BP. Finally, validated criteria
for clinical response assessment in this patient population is needed
for future clinical studies.
Based on the results of this study, we are conducting a phase 2 trial
of decitabine in combination with ruxolitinib at 25 mg bid for an initial
cycle followed by 10 mg bid for subsequent cycles. The rationale for
this approach is based on the observation that although patients
treated with the 25 mg and 50 mg of ruxolitinib attained the greatest
blast count and spleen size reductions, patients treated with 10 mg
bid of ruxolitinib were able to continue on therapy for a longer
duration (10.5 vs 3.5 median number of cycles received in 10-mg
cohort vs 50-mg cohort respectively), suggesting improved
tolerability. Through this approach, we hypothesize that we may be
able to limit potential toxicity of therapy while still administering
clinically efficacious dosing of the treatment regimen. Finally, given
that these data have demonstrated that the combination of
ruxolitinib and decitabine was safe and tolerable in this patient
population, this regimen may serve as a basis to which other
novel/targeted therapeutic agents may be added to further
improve efficacy.
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